TP53 and sarcoma: On repeat genomic profiling (TP53 p.W53*), potential sensitivities were suggested to buparlisib + paclitaxel (head and neck cancer), adavosertib, pazopanib + vorinostat (sarcoma), and GDC-0575 + gemcitabine (sarcoma).